Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 9 Brain Neoplasms 3 Recurrence 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Squamous Cell Carcinoma of Head and Neck 1 Skin Squamous Cell Cancer 1 Rare Tumor 1 Penile Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 NSCLC 1 Lung Neoplasms 1 Carcinoma 1 Advanced Gastric Cancer 1

Interventions

pembrolizumab 5 Nivolumab 4 Cisplatin 4 Paclitaxel 3 Ifosfamide 3 avelumab 2 aldesleukin 2 Radiotherapy 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 vinflunine 1 toripalimab 1 rocakinogene sifuplasmid 1 niraparib 1 nimotuzumab 1 lenvatinib 1 fludarabine phosphate 1 fludarabine 1 enfortumab vedotin 1 durvalumab 1 dostarlimab 1 dacomitinib 1 cemiplimab 1 cabozantinib 1 cabazitaxel 1 Vorinostat 1 VGX-3100 1 Specimen Handling 1 Ritonavir 1 Neoadjuvant Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Penile Neoplasms × dacomitinib × Clear all

NCT01728233 2021-05-14

HER-Uro01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Carcinoma, Squamous Cell, Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡